Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications

References

• Teal S, Edelman A. Contraception selection, effectiveness, and adverse effects: a review. JAMA. 2021 Dec 28;326(24):2507–2518. doi: 10.1001/jama.2021.21392
   PubMed Web of Science ®Google Scholar
• Mawet M, Gaspard U, Foidart JM. Estetrol as estrogen in a combined oral contraceptive, from the first in-human study to the contraceptive efficacy. Eur J Obstet Gynecol Reprod. 2021;3(1):13–21.
   Google Scholar
• Zucconi G, Lisboa BP, Simonitsch E, et al. Isolation of 15-alpha-hydroxy-oestriol from pregnancy urine and from the urine of newborn infants. Acta Endocrinol (Copenh). 1967 Nov;56(3):413–423. doi: 10.1530/acta.0.0560413
   PubMedGoogle Scholar
• Schwers J, Eriksson G, Diczfalusy E. Metabolism of oestrone and oestradiol in the human foeto-placental unit at midpregnancy. Acta Endocrinol (Copenh). 1965 May;49(1):65–82. doi: 10.1530/acta.0.0490065
   PubMedGoogle Scholar
• Gérard C, Arnal JF, Jost M, et al. Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. Expert Rev Clin Pharmacol. 2022 Feb;15(2):121–137. doi: 10.1080/17512433.2022.2054413
   PubMed Web of Science ®Google Scholar
• Rapkin AJ, Winer SA. Drospirenone: a novel progestin. Expert Opin Pharmacother. 2007 May;8(7):989–999. doi: 10.1517/14656566.8.7.989
   PubMed Web of Science ®Google Scholar
• Chiara Del Savio M, Grandi G, Facchinetti F, et al. Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol. 2020 Jul;13(7):685–694. doi: 10.1080/17512433.2020.1783247
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29–38. doi: 10.1016/S0010-7824(00)00133-5
   PubMed Web of Science ®Google Scholar
• Arnal JF, Lenfant F, Metivier R, et al. Membrane and Nuclear Estrogen Receptor Alpha Actions: From Tissue Specificity to Medical Implications. Physiol Rev. 2017 Jul 1;97(3):1045–1087. doi: 10.1152/physrev.00024.2016
   PubMed Web of Science ®Google Scholar
• Foidart JM, Gaspard U, Pequeux C, et al. Unique vascular benefits of estetrol, a native fetal estrogen with specific actions in tissues (NEST). In: Brinton R, Genazzani A, Simoncini T Stevenson J, editors. Sex steroids’ effects on brain, heart and vessels: volume 6: frontiers in gynecological endocrinology [internet]. Cham: Springer International Publishing; 2019. [cited 2023 Apr 18]. p. 169–195. ISGE SeriesAvailable from. doi: 10.1007/978-3-030-11355-1_12
   Google Scholar
• Pluchino N, Santoro AN, Casarosa E, et al. Effect of estetrol administration on brain and serum allopregnanolone in intact and ovariectomized rats. J Steroid Biochem Mol Biol. 2014 Sep;143:285–290.
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJT, Skouby S, Bouchard P, et al. Ovulation inhibition by estetrol in an in vivo model. Contraception. 2008 Mar;77(3):186–190. doi: 10.1016/j.contraception.2007.11.014
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJT, Heegaard AM, Visser M, et al. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric. 2008;11 Suppl 1:2–14. doi: 10.1080/13697130701798692
   PubMed Web of Science ®Google Scholar
• Benoit T, Valera MC, Fontaine C, et al. Estetrol, a Fetal Selective Estrogen Receptor Modulator, Acts on the Vagina of Mice through Nuclear Estrogen Receptor α Activation. Am J Pathol. 2017 Nov;187(11):2499–2507. doi: 10.1016/j.ajpath.2017.07.013
   PubMed Web of Science ®Google Scholar
• Gallez A, Dias Da Silva I, Wuidar V, et al. Estetrol and Mammary Gland: Friends or Foes? J Mammary Gland Biol Neoplasia. 2021 Sep;26(3):297–308. doi: 10.1007/s10911-021-09497-0
   PubMed Web of Science ®Google Scholar
• Visser M, Coelingh Bennink HJT. Clinical applications for estetrol. J Steroid Biochem Mol Biol. 2009 Mar;114(1–2):85–89. doi: 10.1016/j.jsbmb.2008.12.013
   PubMed Web of Science ®Google Scholar
• Regidor PA, Mueller A, Mayr M. Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen. Womens Health. 2023;19:17455057221147388. doi: 10.1177/17455057221147388
   Web of Science ®Google Scholar
• Lee A, Syed YY. Estetrol/Drospirenone: A Review in Oral Contraception. Drugs. 2022 Jul;82(10):1117–1125. doi: 10.1007/s40265-022-01738-8
   PubMed Web of Science ®Google Scholar
• Duijkers I, Klipping C, Kinet V, et al. Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function. Contraception. 2021 Jun;103(6):386–393. doi: 10.1016/j.contraception.2021.03.003
   PubMed Web of Science ®Google Scholar
• Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021 Apr;103(4):213–221. doi: 10.1016/j.contraception.2021.01.001
   PubMed Web of Science ®Google Scholar
• Douxfils J, Klipping C, Duijkers I, et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception. 2020;102(6):396–402.
   PubMed Web of Science ®Google Scholar
• Gérard C, Blacher S, Communal L, et al. Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation. J Endocrinol. 2015 Jan;224(1):85–95. doi: 10.1530/JOE-14-0549
   PubMed Web of Science ®Google Scholar
• Visser M, Holinka CF, Coelingh Bennink HJT. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women. Climacteric. 2008;11 Suppl 1:31–40. doi: 10.1080/13697130802056511
   PubMed Web of Science ®Google Scholar
• Jirku H, Kadner S, Levitz M. Pattern of estetrol conjugation in the human. Steroids. 1972 Apr 1;19(4):519–534. doi: 10.1016/S0039-128X(72)80019-9
   PubMed Web of Science ®Google Scholar
• Santen RJ, Yue W, Wang JP. Estrogen metabolites and breast cancer. Steroids. 2015 Jul;99(Pt A):61–66. doi: 10.1016/j.steroids.2014.08.003
   PubMedGoogle Scholar
• Bagot CN, Marsh MS, Whitehead M, et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost. 2010 Aug;8(8):1736–1744. doi: 10.1111/j.1538-7836.2010.03953.x
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJT, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;11 Suppl 1:47–58. doi: 10.1080/13697130802073425
   PubMed Web of Science ®Google Scholar
• Hammond GL, Hogeveen KN, Visser M, et al. Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells. Climacteric. 2008;11 Suppl 1:41–46. doi: 10.1080/13697130701851814
   PubMed Web of Science ®Google Scholar
• Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995 Jun 12;761(1):311–335. doi: 10.1111/j.1749-6632.1995.tb31386.x
   PubMedGoogle Scholar
• Elger W, Beier S, Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003 Nov;68(10–13):891–905. doi: 10.1016/j.steroids.2003.08.008
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord. 2002 Sep 1;3(3):211–224. doi: 10.1023/A:1020072325818
   PubMedGoogle Scholar
• Mayne Pharma. Nextstellis®(estetrol/drospirenone) tablets: US prescribing information. [Internet]. 2021 [cited 2023 Mar 11]. Available from: https://dailymed.nlm.nih.gov/
   Google Scholar
• European Medicines Agency. Lydisilka (estetrol/drospirenone) tablets: EU summary of product characteristics. 2022. Available from: https://www.ema.europa.eu/
   Google Scholar
• Richter WH, Koytchev R, Kirkov V, et al. Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. Contraception. 2020 Feb;101(2):137–143. doi: 10.1016/j.contraception.2019.10.005
   PubMed Web of Science ®Google Scholar
• Kiley J, Hammond C. Combined oral contraceptives: a comprehensive review. Clin Obstet Gynecol. 2007 Dec;50(4):868–877. doi: 10.1097/GRF.0b013e318159c06a
   PubMed Web of Science ®Google Scholar
• Kost K, Singh S, Vaughan B, et al. Estimates of contraceptive failure from the 2002 national survey of family growth. Contraception. 2008 Jan;77(1):10–21. doi: 10.1016/j.contraception.2007.09.013
   PubMed Web of Science ®Google Scholar
• Huber LRB, Hogue CJ, Stein AD, et al. Contraceptive use and discontinuation: findings from the contraceptive history, initiation, and choice study. Am J Obstet Gynecol. 2006 May;194(5):1290–1295. doi: 10.1016/j.ajog.2005.11.039
   PubMed Web of Science ®Google Scholar
• Mawet M, Maillard C, Klipping C, et al. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur J Contracept Reprod Health Care. 2015;20(6):463–475.
   PubMed Web of Science ®Google Scholar
• Duijkers IJM, Klipping C, Zimmerman Y, et al. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study. Eur J Contracept Reprod Health Care. 2015;20(6):476–489.
   PubMed Web of Science ®Google Scholar
• Grandi G, Del Savio MC, Lopes da Silva-Filho A, et al. Estetrol (E4): the new estrogenic component of combined oral contraceptives. Expert Review Of Clinical Pharmacology. 2020 Apr;13(4):327–330. doi: 10.1080/17512433.2020.1750365
   PubMed Web of Science ®Google Scholar
• Apter D, Zimmerman Y, Beekman L, et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Health Care. 2017 Aug;22(4):260–267. doi: 10.1080/13625187.2017.1336532
   PubMed Web of Science ®Google Scholar
• Archer DF, Mansour D, Foidart JM. Bleeding patterns of oral contraceptives with a cyclic dosing regimen: an overview. J Clin Med. 2022 Aug 8;11(15):4634. doi: 10.3390/jcm11154634
   PubMed Web of Science ®Google Scholar
• Creinin MD, Westhoff CL, Bouchard C, et al. Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. Contraception. 2021 Sep;104(3):222–228. doi: 10.1016/j.contraception.2021.05.002
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Apter D, Zatik J, et al. Estetrol-drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia. BJOG. 2022 Jan;129(1):63–71. doi: 10.1111/1471-0528.16840
   PubMed Web of Science ®Google Scholar
• Grossman D, White K, Hopkins K, et al. Contraindications to combined oral contraceptives among over-the-counter compared with prescription users. Obstet Gynecol. 2011 Mar;117(3):558–565. doi: 10.1097/AOG.0b013e31820b0244
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Achilles SL, Zatik J, et al. Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol/drospirenone on bleeding patterns in healthy women. Contraception. 2022 Dec;116:29–36. doi: 10.1016/j.contraception.2022.07.010
   PubMed Web of Science ®Google Scholar
• Jensen JT, Kaunitz AM, Achilles SL, et al. Pooled efficacy results of estetrol/drospirenone combined oral contraception phase 3 trials. Contraception. 2022 Dec;116:37–43. doi: 10.1016/j.contraception.2022.07.009
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Safety, efficacy, tolerability and pharmacokinetics of LF111 (drospirenone 4.0 mg) during 13 cycles. 2019 [cited 2023 22 Oct]. Available from: https://clinicaltrials.gov/ct2/show/NCT02269241?term=NCT02269241&draw=2&rank=1.
   Google Scholar
• Chen MJ, Jensen JT, Kaunitz AM, et al. Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: pooled analysis of two multicenter, open-label phase 3 trials. Contraception. 2022 Dec;116:44–50. doi: 10.1016/j.contraception.2022.10.004
   PubMed Web of Science ®Google Scholar
• Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011 Oct 25;343(oct25 4):d6423–d6423. doi: 10.1136/bmj.d6423
   PubMedGoogle Scholar